For the quarter ending 2025-09-30, CL had $64M increase in cash & cash equivalents over the period. $1,106M in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|
| Net income including noncontrolling interests | 767 | 773 | 726 | 779 |
| Depreciation and amortization | 158 | 151 | 148 | 148 |
| Erisa litigation matter | 0 | 0 | 65 | 0 |
| Restructuring and termination benefits, net of cash | -2 | -6 | -7 | -3 |
| Stock-based compensation expense | 72 | 32 | 23 | 27 |
| Gain on the sale of land | - | - | - | 0 |
| Goodwill and intangible assets impairment charges | - | - | - | 0 |
| Deferred income taxes | 25 | 7 | -24 | 21 |
| Receivables | 28 | -22 | 174 | -128 |
| Inventories | -6 | -89 | 86 | 6 |
| Accounts payable and other accruals | 278 | -191 | -57 | 189 |
| Other non-current assets and liabilities | 15 | -7 | 14 | 14 |
| Net cash provided by (used in) operations | 1,261 | 884 | 600 | 1,269 |
| Capital expenditures | 155 | 108 | 124 | 184 |
| Purchases of marketable securities and investments | 153 | 250 | 134 | 216 |
| Proceeds from sale of marketable securities and investments | 158 | 253 | 97 | 304 |
| Payment for acquisition, net of cash acquired | - | 293 | - | 0 |
| Proceeds from the sale of land | - | - | - | 0 |
| Payment for acquisition, net of cash acquired | 293 | - | - | - |
| Other investing activities | 4 | 3 | -2 | -16 |
| Net cash provided by (used in) investing activities | -154 | -401 | -159 | -80 |
| Short-term borrowing (repayment) less than 90 days, net | 169 | -194 | 164 | -244 |
| Principal payments of debt | 516 | 135 | 4 | 1 |
| Proceeds from issuance of debt | 0 | 497 | 0 | 0 |
| Dividends paid | 420 | 474 | 406 | 514 |
| Purchases of treasury shares | 288 | 232 | 284 | 455 |
| Proceeds from exercise of stock options | 18 | 25 | 40 | 27 |
| Other financing activities | 9 | 104 | 32 | -92 |
| Net cash provided by (used in) financing activities | -1,028 | -409 | -458 | -1,279 |
| Effect of exchange rate changes on cash and cash equivalents | -15 | 29 | 33 | -48 |
| Net increase (decrease) in cash and cash equivalents | 64 | 103 | 16 | -138 |
| Cash and cash equivalents at beginning of period | 1,215 | 1,112 | 1,096 | 1,234 |
| Cash and cash equivalents at end of period | 1,279 | 1,215 | 1,112 | 1,096 |
COLGATE PALMOLIVE CO (CL)
COLGATE PALMOLIVE CO (CL)